Free LLS Education Program: Multiple Myeloma

Next up in the Leukemia & Lymphoma Society's free telephone and web education programs is this one concerning multiple myeloma.

This program, "Living with Myeloma: Managing Side Effects and Quality of Life," will take place on Wednesday, April 8, 2015 from 1:00 p.m. until 2:30 p.m. EST.
Program host and speaker is Sagar Lonial, MD, FACP, Professor and Executive Vice Chair, Department of Hematology and Medical Oncology, Chief Medical Officer, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.

Topics cover disease monitoring and treatment options

Participation is free, but you must register first. By participating, you can learn more about:

  1. Current and emerging treatments for myeloma
  2. Monitoring disease progression
  3. Managing symptoms and treatment-related side effects
  4. Discussing quality of life issues with your healthcare team

To register by phone, call (855) 676-7723.

To register online, follow this link.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap